SIC
ACAD icon

SJS Investment Consulting’s Acadia Pharmaceuticals ACAD Stock Holding History

SJS Investment Consulting’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$713 Sell
32
-9
-22% -$215 ﹤0.01% 1599
2025
Q4 		$1.1K Buy
41
+32
+356% +$765 ﹤0.01% 1270
2025
Q3 		$193 Hold
9
– – ﹤0.01% 1472
2025
Q2 		$195 Buy
+9
New +$167 ﹤0.01% 1374

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

SJS Investment Consulting's ACAD Position: Q1 2026 in Review

SJS Investment Consulting reduced its Acadia Pharmaceuticals (ACAD) stake by 22% in Q1 2026, selling an estimated $215 and leaving 32 shares worth $713. The position accounts for ﹤0.01% of the portfolio, ranked #1599.

SJS Investment Consulting first reported a position in ACAD in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.1K in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • SJS Investment Consulting held 32 shares of Acadia Pharmaceuticals worth $713 as of Q1 2026.
  • SJS Investment Consulting sold 9 Acadia Pharmaceuticals shares in Q1 2026, an estimated $215.
  • Acadia Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2026, its #1599 holding.
  • SJS Investment Consulting first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • SJS Investment Consulting's Acadia Pharmaceuticals position peaked at $1.1K in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.